Study to Evaluate the Safety and Pharmacokinetics of UTTR1147A in Combination With Standard of Care in Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation


Study Number
463719
Phase
IB
Age Group
Adult
Purpose

This is a Phase Ib, open-label, multicenter, dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of UTTR1147A and to make a preliminary assessment of activity of UTTR1147A in combination with standard-of-care (SOC) in the prevention of acute graft-versus-host disease (aGVHD) in participants undergoing allogeneic hematopoietic stem cell transplantation (HSCT).

Full Title

A PHASE Ib, OPEN-LABEL, DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF UTTR1147A IN COMBINATION WITH STANDARD OF CARE IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

ClinicalTrials.Gov ID
NCT04539470

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.